Lecocq M, Poncin A, Sautois B
Service d'Oncologie médicale, CHU Liège, Belgique.
Rev Med Liege. 2021 May;76(5-6):398-402.
Current recommendations for systemic treatments of head and neck squamous cell carcinoma have been significantly modified with the advent of immunotherapy for a majority of these cancers. Indeed, immune checkpoint inhibitors are now recommended in metastatic disease and in locoregional recurrence not amenable to a local treatment. PD-L1 positive tumours are eligible for immunotherapy in first line and immunotherapy is also available in second line, after failure of platinum based chemotherapy, regardless of PD-L1 expression. Ongoing clinical trials are exploring the role of immune checkpoint inhibitors in the adjuvant setting as well as with radiotherapy as definitive treatment. Immunotherapy has changed the treatment landscape and has improved the prognosis of patients with head and neck squamous cell carcinoma.
随着免疫疗法的出现，针对大多数此类癌症的头颈部鳞状细胞癌全身治疗的当前建议已被显著修改。事实上，免疫检查点抑制剂现在被推荐用于转移性疾病以及不适用于局部治疗的局部区域复发。PD-L1阳性肿瘤一线可采用免疫疗法，在铂类化疗失败后，无论PD-L1表达情况如何，二线也可采用免疫疗法。正在进行的临床试验正在探索免疫检查点抑制剂在辅助治疗以及作为根治性治疗与放疗联合使用时的作用。免疫疗法改变了治疗格局，改善了头颈部鳞状细胞癌患者的预后。
